20 articles
BioAge's oral NLRP3 inhibitor BGE-102 cut hsCRP by ~85% in weeks, signaling a potential breakthrough in treating chronic inflammation at scale.
Belgian biotech Coultreon raises $125M to advance an oral SIK3 inhibitor that rebalances inflammation rather than suppressing immunity outright.
New research links chronic low-grade inflammation to faster epigenetic aging, measured across four validated biological clocks.
New research reveals how fat-derived molecules naturally shut down inflammation, offering hope for safer arthritis and heart disease treatments.
BioAge's oral drug BGE-102 dramatically reduced hsCRP and IL-6 in obese participants with elevated inflammation, with a strong safety profile.
BioAge's oral drug BGE-102 cut a key cardiovascular risk biomarker by up to 86% in obese patients, rivaling higher doses at just 60mg daily.
BioAge's BGE-102 enters Phase 2 with dramatic Phase 1 CRP reductions, targeting cardiovascular risk through inflammasome blockade.
GlycanAge's Dubrovnik conference targets translating 25 years of inflammaging research into real clinical tools for doctors and patients.
Mesoblast licenses CAR technology to make its stem cell therapies smarter at finding inflamed tissue, targeting IBD and autoimmune disease.
Resolution Therapeutics is advancing engineered macrophage therapies using LNP-mRNA tech to treat liver disease, lung fibrosis, and more.
Scientists boosted a protein that dampens chronic inflammation, and older mice grew stronger, more energetic, and had healthier bones.
Immorta Bio is using AI to move beyond disease treatment toward restoring youthful biology by clearing senescent cells and reviving stem cells.
A new wave of biotechs is targeting aging as a root cause, using encapsulated cells and gene therapy to restore lost proteins and reverse decline.
Head-to-head biologic trials and novel cell therapies signal major advances for autoimmune and inflammatory disease treatment.
Insilico Medicine's ISM8969 targets NLRP3 neuroinflammation and crosses the blood-brain barrier — now in Phase 1 human trials.
Clearing zombie cells then restoring stem cell activity produced far greater lifespan gains than either approach alone.
Scripps Research identifies a molecular switch called SNO-STING that locks brain immune cells in overdrive, damaging nerve connections in Alzheimer's.
A small trial found tocilizumab, an anti-inflammatory drug, cut depression remission rates better than SSRIs by targeting IL-6, not brain chemistry.
Preclinical data show ACD137 rivals leading anti-NGF antibody Tanezumab for pain relief while also offering anti-inflammatory and joint-protective effects.
RTX001, a regenerative macrophage cell therapy, reduced liver inflammation and fibrosis in mouse models ahead of Phase I/II trial results.
